A Study to Assess the Effects of ACI-24.060
Phase 1/2
176
about 4 years
35–85
7 sites in AZ, IN, KS +4
What this study is about
This trial is testing a treatment called ACI-24.060 in people with prodromal Alzheimer's disease and adults with Down syndrome who don't have dementia yet. The goal is to see if this treatment is safe, well-tolerated, causes any immune reactions, and how it affects the body.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive ACI-24.060 at Dose A
- 2.Receive ACI-24.060 at Dose B
- 3.Receive ACI-24.060 at Dose C
- +2 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Change from baseline in Anti-Abeta antibody titers in blood, Number of participants with Adverse Events (AEs) assessed by intensity (mild, moderate or severe) and causal relationship (unrelated, unlikely, possibly or probably related), Number of participants with abnormal MRI results
Secondary: Change from baseline in Anti-Abeta antibody titers, Change from baseline on brain amyloid levels
Neurology